
Company Location

400 N. 5th Street, Suite 1600
Phoenix, AZ 85004

Contact Numbers

Tel: (602) 343-8469
Fax: (602) 343-8484

Contact

Theresa C. Olson
Title: Director
tolson@tgen.org

Overview:

The Center for Translational Drug Development, LLC ("TD2 ") is a contract research organization dedicated to translating genomics discoveries into advances in human health by developing new drugs for the prevention and treatment of cancer.

In Vivo Efficacy Evaluation

- Human Tumor Xenograft Models
- Acute Toxicity
- Pharmacokinetics

Genomics Support

- Tissue Microarrays
- DNA Sequencing
- Gene Expression Profiling
- In Situ Hybridization Gene Expression Profiling

DNA/RNA Quantitative PCR

- Biodistribution analysis for gene therapy studies
- Custom assays available upon request

Formulation Development

- Preparation of dosing formulations of test articles
- Non-GLP/GMP stability studies

In Vitro Evaluation of Anticancer Agents

- Apoptosis Studies
- Potency Testing
- Dosing Studies
- Human Tumor Cloning Assays
- Target Detection (IHC, In vivo imaging, microarray)

Clinical Trials

- Feasibility Studies
- Investigator Selection Strategies
- Phase I Study Design by Medical Oncologists
- Protocol Design
- Trial Coordination

TD2's Added Value

Merely supplementing a client's infrastructure only completes half of the equation. Without the specialized expertise needed to drive early-stage drug development, the likelihood that outsourcing will provide a client with a financial advantage remains the same. By designing relevant preclinical studies that are driven by the clinical trial design, TD2 completes the equation by better positioning the drug candidate for clinical and commercial success—an added value that draws the interest of the investment community.

Equipment and Technology

1. Over 10,000 square feet of wet and dry laboratory space
2. High-throughput, state of the art lab using one of the most advanced DNA Sequencing platforms currently on the market with Applied Biosystems 3730xl and 3100 automated sequencers, supported by robotic automation
3. Bioinformatics-the 1,024-CPU IBM Supercomputer cluster
4. End-to-end solution for high-throughput SNP genotyping.

Benefits of TD2

Our focus is to implement appropriate translational research to contribute to the successful development of drug discovery. We have established novel research programs and expedited findings that will positively impact individuals with diabetes, autism, prostate and breast cancer, melanoma, and gastric cancer, to name a few. Our research divisions are disease focused and supported by a strong base of core technology platforms that will allow research to be done on a large scale and short timeframe.

